US REFORM HEALTHY FOR BRISBANE'S BIOLOGICS

Written on the 13 April 2010

US REFORM HEALTHY FOR BRISBANE'S BIOLOGICS

THE national biotechnology body says recent US health reforms will ‘change the game’ for Australian biologics companies, with patent life extension for products including vaccines and allergenics.

AusBiotech CEO Dr Anna Lavelle, says the US health reforms change the Hatch-Waxman Act, increasing biologic patent life extensions from five to 12 years.

“The game is changing and it means that some biologic technologies that may have been put in the drawer before will now have a more reasonable return on investment, factoring in longer times before generics get to the market,” she says.

“It could be significant because with the big pharma companies looking at their project pipelines, about 25 per cent of those in the pipeline are biologic and by 2025 it could grow to about 50 per cent.

“Before they had the two mistresses of speed and getting it right, but this takes the weight off significantly and that’s good news.”

She says while biotech companies will benefit because they will have more time to perfect their products, generics companies are looking at the situation ‘philosophically’.

For Brisbane-based Alchemia, the patent life extension will mean delays for some of its biologics products under development, dealing with the delivery of ‘super generics’ that can only be released once patent exclusivity expires.

CEO Dr Pete Smith (pictured), says the US health reform is good overall for the biotech sector but it’s ‘not a great sea change’, as increased access to pharmaceuticals will be partially offset by a push for affordability.

“Longer patent lives mean we will have to wait longer before we get to delivery on the market. The matter is that we’ll see patients able to receive drugs more widely, but there will be a push for affordability so the net value for pharmaceuticals will be quite neutral,” he says.


Latest News

SLATER AND GORDON TAKES SPOTLESS TO COURT

SPOTLESS Group (ASX: SPO) has been hit by a class action launched by Slater and Gordon (ASX: SGH) in the Federal C...

ANSELL'S SHARE PRICE SWELLS AFTER SALE OF CONDOM BUSINESS

IT'S one of Australia's most successful and enduring manufacturing success stories and the Ansell condom busi...

TOPSHOP GOES INTO ADMINISTRATION AMID VOLATILE RETAIL MARKET

TOPSHOP has become the latest in a string of retailers blasted by the volatile retail market, as the iconic fashio...

SIGMA'S SHARE PRICE TAKES A BATTERING AS IT LAUNCHES LEGAL ACTION OVER SUPPLY DEAL

SIGMA Healthcare (ASX: SIG) has taken the MyChemist and Chemist Warehouse chains to court to demand they continue to ...

Related News

SLATER AND GORDON TAKES SPOTLESS TO COURT

SPOTLESS Group (ASX: SPO) has been hit by a class action launched by Slater and Gordon (ASX: SGH) in the Federal C...

TOPSHOP GOES INTO ADMINISTRATION AMID VOLATILE RETAIL MARKET

TOPSHOP has become the latest in a string of retailers blasted by the volatile retail market, as the iconic fashio...

SIGMA'S SHARE PRICE TAKES A BATTERING AS IT LAUNCHES LEGAL ACTION OVER SUPPLY DEAL

SIGMA Healthcare (ASX: SIG) has taken the MyChemist and Chemist Warehouse chains to court to demand they continue to ...

REGIONAL BANKS HIT OUT AT RATING CUT AND WARN BIG FOUR WILL BENEFIT

REGIONAL banks have hit out at a downgrade on their credit ratings, warning that it will increase their wholesale fun...

BOOK YOUR FUNCTION SPACE HERE

 

 

 

Contact us

Email News Update Sign Up Contact Details
Subscriptions

PO Box 2087
Brisbane QLD 4001

LoginTell a FriendSign Up to Newsletter